BerGenBio ASA (FRA:7BG0)
€ 0.708 0.009 (1.29%) Market Cap: 28.14 Mil Enterprise Value: 13.42 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 58/100

Q3 2024 Bergenbio ASA Earnings Call Transcript

Nov 13, 2024 / 09:00AM GMT
Release Date Price: €0.538 (-11.22%)
Martin Olin
Bergenbio ASA - Chief Executive Officer

Mutation is really characterized by having a high incidence of a negative PDL one expression, meaning that they are not likely to benefit from checkpoint inhibition. And this graph shows that STK 11 actually has the higher number, highest number of a negative PDL one expression.

Also newly announced data confirms that the significant unmet medical need is actually relevant from a number of medical viewpoints. One is the overall response rate which is significantly lower than the wild type situation, but also which is very meaningful for the patients is that even if you would respond, the immediate overall or progression free survival over survival is significantly lower than the wild type with statistical significance. So, this all points to what I said before, a significant nonmed medical need and no targeted therapies available.

This translates into a significant market opportunity in the Western world. We believe this is around 30,000 patients on an annual basis that will be eligible for the treatment, combination of the sentiment

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot